Loading…

Optimization of garlic (Allium sativum) inhibitory activity against Propionibacterium acnes

The use of plants as the main ingredients of treatment has become part of the culture of almost every country in the world. One of the plants that have medicinal properties is garlic (Allium sativum L.). Garlic has been used as an antibacterial. Its compounds such as allicin, and ajoene is known to...

Full description

Saved in:
Bibliographic Details
Main Authors: Kunaedi, Aan, Hidayati, Nur Rahmi, Indawati, Iin, Suharyani, Ine, Indriaty, Sulistiorini, Karlina, Nina, Angraeni, Siti Anggi
Format: Conference Proceeding
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of plants as the main ingredients of treatment has become part of the culture of almost every country in the world. One of the plants that have medicinal properties is garlic (Allium sativum L.). Garlic has been used as an antibacterial. Its compounds such as allicin, and ajoene is known to have antibacterial activity, against gram-positive and gram-negative, antifungal such as Candida sp, antiviral and antiparasitic, including intestinal protozoa such as Giardia lambria and Entamoeba histolitica, and also Propionibacterium acnes. This study aims to determine the effectiveness of garlic (Allium sativum L.) concentrate against Propionibacterium acnes growth. Garlic concentrations was 5%, 10% and 20%. The inhibitory activity was done by using the diffusion method by comparing aquades as negative control and Clindamycin 0.01% as a positive control. These results showed that there was an inhibitory effect on Propionibacterium acnes. The widest inhibition diameter 20% garlic concentrate was 1.81 cm, with the r value is 0.99. These results showed that there was a very strong relationship between the concentration of garlic concentrate to inhibition of Propionibacterium acnes growth. This research is useful, as a scientific basis for the development of further research and clinical trials.
ISSN:0094-243X
1551-7616
DOI:10.1063/5.0121026